C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lowered its position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 84.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,167 shares of the company's stock after selling 189,249 shares during the period. Marshall Wace LLP owned 0.05% of C4 Therapeutics worth $130,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Wasatch Advisors LP increased its stake in shares of C4 Therapeutics by 7.0% in the fourth quarter. Wasatch Advisors LP now owns 6,072,601 shares of the company's stock valued at $21,861,000 after buying an additional 395,233 shares during the period. Geode Capital Management LLC raised its stake in shares of C4 Therapeutics by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,381,086 shares of the company's stock valued at $4,973,000 after acquiring an additional 11,410 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of C4 Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 486,366 shares of the company's stock worth $1,751,000 after purchasing an additional 3,437 shares during the period. Barclays PLC increased its holdings in C4 Therapeutics by 38.4% in the third quarter. Barclays PLC now owns 243,457 shares of the company's stock valued at $1,387,000 after purchasing an additional 67,546 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its position in C4 Therapeutics by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 227,147 shares of the company's stock worth $818,000 after purchasing an additional 34,783 shares during the last quarter. 78.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, UBS Group raised C4 Therapeutics to a "hold" rating in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.50.

C4 Therapeutics Price Performance

C4 Therapeutics stock traded down $0.07 during mid-day trading on Friday, reaching $1.47. 1,168,883 shares of the stock traded hands, compared to its average volume of 1,401,634. The business's 50-day moving average is $1.67 and its 200-day moving average is $3.25. The stock has a market capitalization of $104.38 million, a PE ratio of -0.86 and a beta of 3.10. C4 Therapeutics, Inc. has a 12-month low of $1.09 and a 12-month high of $7.66.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.11. C4 Therapeutics had a negative net margin of 313.35% and a negative return on equity of 42.45%. The firm had revenue of $7.20 million during the quarter, compared to analysts' expectations of $3.54 million. Equities analysts anticipate that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.